HomeFile

File

Are There Sex Differences in pLVAD-Assisted High Risk PCI?

The proportion of patients undergoing high risk PCI (HRPCI) is on the rise. It includes patients with...

EuroCTO: Safety and Benefit at 3 Years

Chronic total occlusions (CTOs) account for approximately 15-20% of patients with stable coronary artery disease. This field...

SCOPE I Results at 3 Years: ACURATE Neo vs. SAPIEN 3

Transcatheter aortic valve implantation (TAVI) has become the standard treatment for elderly patients with severe symptomatic aortic...

STREAM-2: Reduced Dosage of Tenecteplase for Patients over 60 Years Old

Reduced dosage of tenecteplase in elderly patients undergoing a pharmaco-invasive strategy. Delays in achieving timely reperfusion in patients...

Device Effectiveness for Femoropopliteal Artery Disease Treatment: Analysis of K-VIS ELLA Registry

Endovascular treatment of lesions in femoropopliteal territory (FPA) has become the main therapeutic option, seeing as it...

ABSORB IV – Improving Bioresorbable Scaffolds: A Long Road

5-year followup of bioresorbable scaffolds in selected and better prepared lesions (ABSORB IV).  Historically, when comparing previously used...

No Reflow after Primary PCI in STEMI: An Angiographic Analysis of the TOTAL Study

In the early days of percutaneous coronary intervention (PCI) in patients with ST elevation acute myocardial infarction...

Mitral Valve Edge to Edge Repair for Papillary Muscle Rupture after Acute Myocardial Infarction

With an approximate incidence of 0.05% to 0.25%, post-acute myocardial infarction (AMI) mitral valve failure caused by...